Roivant Sciences has seen significant stock gains, driven by brepocitinib's expansion across multiple immunology areas and a cash boost from settling with Moderna. The company’s strong balance sheet supports ongoing buybacks and pipeline development. However, its current high valuation reduces the margin of safety and highlights risks ahead. Despite this, Roivant remains appealing for patient investors betting on management’s shift from M&A to revenue growth.
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Bragar Eagel & Squire, P.C. is investigating Starfighters Space, Inc. following the resignation of its founder and CEO Rick Svetkoff and company secretary Brenda Svetkoff due to disagreements with the board over company operations. The company disput...
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
